Screener
Taysha Gene Therapies, Inc. TSHA Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | — | $2,302 |
| Operating expenses: | ||
| Research and development | 33,809 | 15,565 |
| General and administrative | 9,677 | 8,158 |
| Total operating expenses | 43,486 | 23,723 |
| Loss from operations | (43,486) | (21,421) |
| Other (expense) income: | ||
| Change in fair value of warrant liability | — | 102 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s total revenue?
- Taysha Gene Therapies, Inc. (TSHA) reported total revenue of $0 in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s total revenue changed year-over-year?
- Taysha Gene Therapies, Inc.'s total revenue decreased by 100.0% year-over-year, from $2.3M to $0.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s total revenue?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s total revenue has grown at a 57.5% compound annual growth rate (CAGR), from $2.5M to $9.77M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Taysha Gene Therapies, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude